Brokerages expect Bausch Health Companies Inc (NYSE:BHC) to post $2.08 billion in sales for the current fiscal quarter, according to Zacks Investment Research. Six analysts have provided estimates for Bausch Health Companies’ earnings, with the highest sales estimate coming in at $2.16 billion and the lowest estimate coming in at $2.01 billion. Bausch Health Companies posted sales of $2.16 billion during the same quarter last year, which suggests a negative year-over-year growth rate of 3.7%. The company is scheduled to announce its next earnings report on Wednesday, February 27th.
According to Zacks, analysts expect that Bausch Health Companies will report full year sales of $8.32 billion for the current financial year, with estimates ranging from $8.27 billion to $8.36 billion. For the next financial year, analysts expect that the business will report sales of $8.49 billion, with estimates ranging from $8.30 billion to $8.81 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that follow Bausch Health Companies.
Bausch Health Companies (NYSE:BHC) last released its quarterly earnings results on Tuesday, November 6th. The company reported $1.15 EPS for the quarter, beating the consensus estimate of $0.84 by $0.31. Bausch Health Companies had a negative net margin of 40.41% and a positive return on equity of 29.71%. The firm had revenue of $2.14 billion during the quarter, compared to the consensus estimate of $2.09 billion. The business’s revenue for the quarter was down 3.7% on a year-over-year basis.
Several analysts recently commented on the stock. HC Wainwright set a $25.00 price target on shares of Bausch Health Companies and gave the company a “hold” rating in a research report on Monday, October 15th. Zacks Investment Research downgraded shares of Bausch Health Companies from a “buy” rating to a “hold” rating in a research report on Thursday, October 4th. Royal Bank of Canada upped their price objective on shares of Bausch Health Companies from $25.00 to $26.00 and gave the stock a “hold” rating in a research report on Wednesday, August 8th. Wells Fargo & Co restated a “sell” rating on shares of Bausch Health Companies in a research report on Monday, August 6th. Finally, Piper Jaffray Companies set a $13.00 price objective on shares of Bausch Health Companies and gave the stock a “sell” rating in a research report on Monday, July 23rd. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and four have issued a buy rating to the company’s stock. Bausch Health Companies has a consensus rating of “Hold” and a consensus price target of $27.55.
BHC stock opened at $27.20 on Friday. Bausch Health Companies has a 12 month low of $13.86 and a 12 month high of $28.45. The firm has a market capitalization of $9.34 billion, a P/E ratio of 7.10, a price-to-earnings-growth ratio of 0.38 and a beta of -0.28. The company has a quick ratio of 0.89, a current ratio of 1.14 and a debt-to-equity ratio of 6.99.
In other Bausch Health Companies news, EVP Christina Ackermann sold 19,946 shares of the company’s stock in a transaction on Tuesday, October 16th. The shares were sold at an average price of $24.98, for a total transaction of $498,251.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Joseph C. Papa acquired 30,000 shares of the business’s stock in a transaction on Friday, September 14th. The shares were purchased at an average price of $22.32 per share, with a total value of $669,600.00. The disclosure for this purchase can be found here. In the last 90 days, insiders have acquired 165,000 shares of company stock valued at $3,890,700. 11.54% of the stock is owned by insiders.
Institutional investors have recently made changes to their positions in the business. NEXT Financial Group Inc purchased a new position in shares of Bausch Health Companies in the 3rd quarter valued at about $101,000. Steward Partners Investment Advisory LLC purchased a new position in shares of Bausch Health Companies in the 3rd quarter valued at about $106,000. Polaris Greystone Financial Group LLC purchased a new position in shares of Bausch Health Companies in the 3rd quarter valued at about $107,000. Quadrant Capital Group LLC purchased a new position in shares of Bausch Health Companies in the 3rd quarter valued at about $118,000. Finally, Bedel Financial Consulting Inc. purchased a new position in shares of Bausch Health Companies in the 3rd quarter valued at about $129,000. Institutional investors own 42.90% of the company’s stock.
About Bausch Health Companies
Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. It offers dermatology products that treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis, cold sores, athlete's foot, nail fungus, and other dermatoses, as well as provides aesthetic medical devices, which address various conditions, including facial wrinkles, acne, pigmentation conditions, body sculpting, skin tightening, and laser hair removal.
Further Reading: What does relative strength index mean?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.